quinazolines has been researched along with Lymphoma of Mucosa-Associated Lymphoid Tissue in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Childs, BH; Dreyling, M; Follows, GA; Garcia-Vargas, J; Hiemeyer, F; Mollica, L; Nagler, A; Özcan, M; Panayiotidis, P; Santoro, A; Stevens, D; Trevarthen, D; Zinzani, PL | 1 |
| Barth, TFE; Buske, C; Dreyhaupt, J; Grunenberg, A; Kaiser, LM; Kiesewetter, B; Möller, P; Muche, R; Raderer, M; Schmelzle, B; Viardot, A; Woelfle, S | 1 |
| Thieblemont, C | 1 |
1 review(s) available for quinazolines and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
1 trial(s) available for quinazolines and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, B-Cell, Marginal Zone; Phosphoinositide-3 Kinase Inhibitors; Prospective Studies; Pyrimidines; Quinazolines | 2021 |
1 other study(ies) available for quinazolines and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Topics: Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines | 2021 |